Agents such as nivolumab and pembrolizumab, monoclonal antibodies that block PD-1 and ipilimumab, a CTLA-4 inhibitor, have demonstrated good responses in HCC patients (Zhang et al., 2022a). The gene discussed is CTLA4; the disease is hepatocellular carcinoma.